Graves' disease and radioiodine therapy: Is success of ablation dependent on the achieved dose above 200 Gy?

NuklearMedizin

Volumn 47, Issue 1, 2008, Pages 13-17

  Kobe, C ^a   Eschner, W ^a   Sudbrock, F ^a   Weber, I ^a   Marx, K ^a   Dietlein, M ^a   Schicha, H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Dosimetry; Graves' disease; Hyperthyroidism; Radioiodine therapy

Indexed keywords

IODINE 131; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; EYE DISEASE; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; THYROID FUNCTION; TREATMENT OUTCOME;

ADULT; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; MIDDLE AGED; ORGAN SIZE; RADIOISOTOPES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; THYROID GLAND; THYROTROPIN;

EID: 39449127301     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0087     Document Type: Article

References (26)

1. 131I used in the treatment of hyperthyroid patients with Graves' disease. Nuklearmedizin 2005; 44: 197-199.
2. Brunn J, Block U, Ruf G et al. Volumetric analysis of thyroid lobes by real-time ultrasound. Dtsch Med Wschr 1981; 106:1338-1340.
3. Dietlein M, Dressler J, Eschner W et al. Procedure guideline for radioiodine test (version 2). Nuklearmedizin 2003; 42: 116-119.
4. Dietlein M, Dressler J, Grünwald F et al. Guideline for radioiodine therapy for benign thyroid diseases (version 3). Nuklearmedizin 2004; 43: 217-220.
5. Dietlein M, Moka D, Reinholz U et al. Who might benefit from administration of additional inactive iodine during radioiodine therapy for Graves' disease? Nuklearmedizin 2007; 46: 77-84.
6. Dominello A, Guinea AmReeve TS, Robinson B et al. Progressive increase in thyroid function after subtotal thyroidectomy for Graves' disease. Asian J Surg 2000; 23:131-135.
7. Dunkelmann S, Neumann V, Staub U et al. Results of a risk adapted and functional radioiodine therapy in Graves' disease. Nuklearmedizin 2005; 44: 238-242.
8. Dunkelmann S, Künstner E, Nabavi U et al. Lithium as an adjunct to radioiodine therapy in Graves' disease for prolonging the intrathyroidal effective half-life of radioiodine. Nuklearmedizin 2006; 45: 213-218.
9. Eschner W, Moka D. Prä- und peritherapeutische Dosimetrie bei der Radioiodtherapie benigner Schilddrüsenerkrankungen. Der Nuklearmediziner 2004; 27: 90-97.
10. 99mTc-uptake in autonomous thyroid tissue in Germany since the 1970s: Clinical implications for radioiodine therapy. Nuklearmedizin 2006; 45: 122-125.
11. Gotthardt M, Rubner C, Bauhofer A et al. What is the best pre-therapeutic dosimetry for successful radioiodine therapy of multifocal autonomy? Nuklearmedizin 2006; 45: 206-212.
12. Koch W, Rosa E, Knesewitsch P et al. Guideline on radiation protection in medicine requires documentation of radioiodine therapy and follow-up: What are the benefits of an electronic database? Nuklearmedizin 2005; 44: 49-55.
13. Ku CF, Lo CY, Chan WF et al. Total thyroidectomy replaces subtotal thyroidectomy as the preferred surgical treatment for Graves' disease. Anz J Surg 2005; 75: 528-531.
14. Meller B, Haase A, Seyfarth M et al. Reduced radioiodine uptake at increased iodine intake and 131I-induced release of "cold" iodine stored in the thyroid. Nuklearmedizin 2005; 44: 137-142.
15. Moka D, Dietlein M, Schicha H. Radioiodine therapy and thyrostatic drugs and iodine. Eur J Nucl Med Mol Imaging 2002; 29 (Suppl 2): 486-491.
16. 131Iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995; 25: 883-884.
17. 131I therapy with 150 Gray in Graves'disease. Nuklearmedizin 1997; 36: 81-86.
18. Reinhardt MJ, Brink I, Joe AY et al. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect on pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging 2002; 29: 1118-1124.
19. Sabri O, Zimny M, Schulz G et al. Success rate of radioiodine therapy in Graves' disease: The influence of thyrostatic medication. J Clin Endocrinol Metab 1999; 84: 1229-1233.
20. Schneider P., Korber C, Korber-Hafner N et al. Does an individual estimation of halflife improve the results of radioiodine therapy of Graves' disease? Nuklearmedizin 2002; 41: 240-244.
21. Snyder WS, Ford MR, Warner GG et al. MIRD Pamphlet No.11: "S" Absorbed dose per unit cumulated activity for selected radionuclides and organs. Society of Nuclear Medicine, New York 1975.
22. Urbannek V. Radioiodtherapie bei Morbus Base-dow - Vergleich verschiedener Therapieregime bezüglich der Thyreostatikagabe. Dissertation, Universität zu Köln 2003.
23. Urbannek V, Schmidt M, Moka D et al. Effect of iodine application during radioiodine therapy in patients with impending therapy failure. Nuklearmedizin 2000; 39: 108-112
24. Willemsen UF, Knesewitsch P, Kreisig T et al. Functional results of radioiodine therapy with a 300 Gy absorbed dose in Graves' disease. Eur J Nucl Med 1993; 20: 1051-1055.
25. Zöphel K, Wunderlich G, Kopprasch C et al. Predictive value of thyrotropin receptor antibodies using the second generation TRAb human assay after radioiodine treatment in Graves' disease. Nuklearmedizin 2003; 42; 63-70.
26. Zöphel K, Wunderlich G, Grüning T et al. Where does subclinical hypothyroidism start? Implications for definition of the upper reference limit for thyroid stimulating hormone. Nuklearmedizin 2005; 44: 56-61.